BioXcel Therapeutics Inc.

30.68-1.35-4.21%Vol 200.21K1Y Perf -26.51%
Sep 24th, 2021 16:00 DELAYED
BID30.68 ASK30.76
Open31.45 Previous Close32.03
Pre-Market- After-Market-
 - -  - -%
Target Price
101.38 
Analyst Rating
Strong Buy 1.00
Potential %
230.44 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
17.04 
Earnings Rating
Buy
Market Cap858.09M 
Earnings Date
11th Nov 2021
Alpha0.06 Standard Deviation0.37
Beta1.06 

Today's Price Range

30.2831.67

52W Range

23.0767.74

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-0.07%
1 Month
13.88%
3 Months
-1.29%
6 Months
-25.48%
1 Year
-26.51%
3 Years
297.92%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BTAI30.68-1.3500-4.21
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-1.03-1.11-7.77
Q01 2021-0.89-1.08-21.35
Q04 2020-0.87-0.870.00
Q03 2020-0.80-1.07-33.75
Q02 2020-0.74-1.06-43.24
Q01 2020-0.55-0.79-43.64
Q04 2019-0.67-0.4532.84
Q03 2019-0.59-0.573.39
Earnings Per EndEstimateRevision %Trend
9/2021 QR-1.084.42Positive
12/2021 QR-1.28-3.23Negative
12/2021 FY-4.49-0.22Negative
12/2022 FY-3.78-26.42Negative
Next Report Date11th Nov 2021
Estimated EPS Next Report-1.08
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume200.21K
Shares Outstanding27.97M
Shares Float18.48M
Trades Count3.47K
Dollar Volume28.44M
Avg. Volume432.50K
Avg. Weekly Volume242.64K
Avg. Monthly Volume270.24K
Avg. Quarterly Volume345.53K

BioXcel Therapeutics Inc. (NASDAQ: BTAI) stock closed at 30.68 per share at the end of the most recent trading day (a -4.21% change compared to the prior day closing price) with a volume of 200.22K shares and market capitalization of 858.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. BioXcel Therapeutics Inc. CEO is Vimal Mehta.

The one-year performance of BioXcel Therapeutics Inc. stock is -26.51%, while year-to-date (YTD) performance is -33.59%. BTAI stock has a five-year performance of %. Its 52-week range is between 23.07 and 67.74, which gives BTAI stock a 52-week price range ratio of 17.04%

BioXcel Therapeutics Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 3.21, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.17%, a ROC of -61.80% and a ROE of -61.67%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioXcel Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. BioXcel Therapeutics Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for BioXcel Therapeutics Inc. is Strong Buy (1), with a target price of $101.38, which is +230.44% compared to the current price. The earnings rating for BioXcel Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioXcel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioXcel Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.26, ATR14 : 1.72, CCI20 : 115.18, Chaikin Money Flow : -0.08, MACD : 0.87, Money Flow Index : 70.83, ROC : 6.31, RSI : 56.39, STOCH (14,3) : 59.27, STOCH RSI : 0.51, UO : 49.64, Williams %R : -40.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioXcel Therapeutics Inc. in the last 12-months were: Frank Yocca (Option Excercise at a value of $6 150), Frank Yocca (Sold 45 000 shares of value $2 318 540 ), Krishnan Nandabalan (Sold 473 250 shares of value $14 589 493 ), Richard I. Steinhart (Option Excercise at a value of $20 813), Richard I. Steinhart (Sold 3 750 shares of value $180 563 ), Vimal Mehta (Sold 473 250 shares of value $14 589 493 ), Vincent O'Neill (Option Excercise at a value of $136 650), Vincent O'Neill (Sold 75 000 shares of value $3 912 335 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.

CEO: Vimal Mehta

Telephone: +1 475 238-6837

Address: 555 Long Wharf Drive, New Haven 06511, CT, US

Number of employees: 40

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

53%47%

TipRanks News for BTAI

Wed, 11 Aug 2021 10:35 GMT Bioxcel Therapeutics (BTAI) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits